# Steroid-Induced Hyperglycemia

Adjust insulin to the glucocorticoid’s timing and glucose pattern, prioritize postprandial surveillance, treat persistent hyperglycemia with scheduled insulin, and reduce insulin promptly as steroid exposure falls to prevent hypoglycemia.

**Clinical question:** How should clinicians monitor and adjust insulin for hyperglycemia caused or worsened by systemic glucocorticoids?

Updated: 2026-09-15T18:28:18.342729+00:00

## What matters in practice
- Initiate bedside point-of-care glucose testing in every patient receiving glucocorticoid therapy, whether or not diabetes was previously diagnosed. [12]
- Do not rely on fasting glucose alone after a single morning intermediate-acting glucocorticoid dose; postprandial hyperglycemia is typically more pronounced and fasting testing can miss clinically important dysglycemia. [18][22]
- Persistent hyperglycemia during glucocorticoid exposure warrants scheduled insulin therapy; match insulin timing and action profile to the steroid regimen. [11][1]
- For steroid-treated patients, reduce glucose-lowering treatment when the steroid dose is substantially reduced; failure to down-titrate is a frequent cause of hypoglycemia. [1]
- Send patients for emergency assessment when glucose exceeds 15 mmol/L (270 mg/dL) with ketones above 2 mmol/L, or when glucose is persistently above 20 mmol/L (360 mg/dL) or reads "HI." [1]

## Identify emergencies and establish the steroid-linked glucose pattern

Separate hyperglycemic crisis from routine insulin adjustment before changing outpatient or ward regimens.

Refer directly for emergency assessment when blood glucose is greater than 15 mmol/L (270 mg/dL) with ketones greater than 2 mmol/L, indicating high risk for diabetic ketoacidosis, or when glucose is persistently greater than 20 mmol/L (360 mg/dL) or registers as "HI," suggesting hyperosmolar hyperglycemic state risk. [1]

For nonemergent patients, document the glucocorticoid agent, dose, route, dosing frequency, and anticipated taper or stop date before selecting insulin. Glucocorticoids increase hepatic glucose production, impair peripheral glucose uptake, and increase insulin resistance; the clinical result is commonly disproportionate postprandial rather than fasting hyperglycemia. [13][22]

Obtain bedside point-of-care glucose monitoring for any inpatient receiving glucocorticoids, including patients without known diabetes. A random glucose above 140 mg/dL identifies inpatient hyperglycemia requiring clinical attention, while repeated values of at least 11.1 mmol/L (200 mg/dL) during steroid exposure support steroid-induced hyperglycemia in a patient without prior diabetes. [12][2][1]
- Record a baseline HbA1c when feasible: a newly elevated HbA1c of at least 6.5% plus steroid-associated hyperglycemia is categorized as steroid-induced diabetes in the cited consensus framework. [1]
- Interpret an elevated HbA1c as evidence of more sustained dysglycemia, but do not defer treatment while awaiting it when repeated point-of-care glucose values are elevated. [1][12]
- Treat acute illness, enteral or parenteral nutrition, and preexisting diabetes as concurrent contributors; glucocorticoids may exacerbate established diabetes, unmask previously undiagnosed diabetes, or cause new dysglycemia. [18]

*Glucose thresholds that change immediate management in steroid-treated patients. [1][2]*

| Finding | Interpretation | Immediate action |
| --- | --- | --- |
| Random glucose >140 mg/dL | Inpatient hyperglycemia threshold for clinical evaluation. [2] | Begin or intensify point-of-care monitoring and review steroid timing, nutrition, and current diabetes therapy. [2][12] |
| Repeated glucose ≥200 mg/dL during steroid exposure | Steroid-induced hyperglycemia criterion in a patient without prior diabetes. [1] | Institute a scheduled glucose-lowering plan; persistent hyperglycemia on glucocorticoids warrants insulin therapy. [11] |
| Glucose >270 mg/dL plus ketones >2 mmol/L | High risk for diabetic ketoacidosis. [1] | Refer for emergency hospital assessment and management. [1] |
| Glucose persistently >360 mg/dL or meter reads "HI" | Hyperosmolar hyperglycemic state risk. [1] | Refer for emergency hospital assessment and management. [1] |

## Measure glucose when the glucocorticoid is most likely to raise it

The sampling schedule should detect the steroid effect rather than falsely reassure with a normal fasting value.

With most glucocorticoid regimens, preferentially assess postprandial glucose because glucocorticoid exposure produces greater postprandial than fasting hyperglycemia. A normal fasting result does not exclude clinically meaningful steroid-induced hyperglycemia, particularly after a single morning dose of an intermediate-acting agent. [22][18]

For cyclic or intermittent high-dose steroid regimens, obtain glucose screening before each treatment cycle and again 4 to 6 hours after glucocorticoid intake. This approach detected steroid-associated hyperglycemia in hematologic patients and targets the expected early rise after dosing. [10]

Reassess glucose values whenever the glucocorticoid dose, timing, formulation, or frequency changes. Insulin needs follow steroid exposure; a regimen that is adequate during high-dose therapy can cause hypoglycemia after a steroid reduction or discontinuation. [1]
- Ask patients receiving outpatient glucose-lowering therapy to recognize and respond to hypoglycemia, especially during a steroid taper. [1]
- Provide explicit return precautions for severe hyperglycemia symptoms and emergency glucose or ketone thresholds rather than relying on routine follow-up. [1]
- Do not use fasting glucose as the sole screening test for a patient receiving single morning intermediate-acting glucocorticoids. [18]

*Monitoring priorities by steroid-use context. [10][12][18][22]*

| Clinical context | Most informative monitoring approach | What changes management |
| --- | --- | --- |
| Any hospitalized patient receiving glucocorticoids | Initiate bedside point-of-care glucose testing irrespective of diabetes history. [12] | Persistent hyperglycemia triggers scheduled insulin therapy. [11] |
| Single morning intermediate-acting glucocorticoid | Check postprandial values; fasting glucose may underestimate dysglycemia. [18][22] | Postprandial elevation supports steroid-patterned insulin adjustment rather than reassurance from fasting values. [18] |
| Intermittent high-dose steroid cycle | Screen before each cycle and 4-6 hours after steroid administration. [10] | Repeated elevations during cycles justify a reproducible cycle-specific treatment plan. [10] |
| Steroid taper or discontinuation | Review glucose trends and insulin exposure with each meaningful steroid reduction. [1] | Reduce glucose-lowering treatment to limit hypoglycemia. [1] |

## Use scheduled insulin matched to steroid exposure

Persistent steroid-related hyperglycemia is managed with insulin; select the basal strategy around steroid duration and dosing pattern.

Initiate insulin for persistent hyperglycemia while the patient is receiving glucocorticoid therapy. In moderate to severe steroid-induced hyperglycemia, insulin is the principal treatment approach; morning intermediate-acting isophane insulin or morning mixed insulin can be matched to the glycemic effect of steroid treatment. [11][1]

For a morning intermediate-acting glucocorticoid regimen with predominantly later-day glucose elevation, consider morning NPH/isophane insulin because its action profile can be aligned to the anticipated steroid-related glucose rise. If the patient requires a basal-bolus regimen, either NPH or insulin glargine can serve as basal insulin: a randomized trial in hospitalized adults with type 2 diabetes, respiratory disease, and medium- to high-dose intermediate-acting corticosteroids found the two basal strategies equally effective within a basal-bolus protocol. [1][8]

For long-acting dexamethasone or intermediate-acting methylprednisolone associated with hyperglycemia throughout the day, do not assume a single fasting measurement captures control. Use serial glucose results across the day to judge whether the current basal-bolus exposure covers the sustained pattern. [13][22]
- Avoid correction-only thinking when elevations persist: the Endocrine Society guideline recommends insulin therapy for persistent hyperglycemia during glucocorticoid treatment. [11]
- If selecting NPH versus glargine as basal insulin in a hospitalized patient with type 2 diabetes receiving intermediate-acting corticosteroids, recognize that trial evidence found similar efficacy when both were used as part of basal-bolus therapy. [8]
- Evaluate each insulin change against the actual steroid dose and timing, not against fasting glucose alone. [1][18]

### When noninsulin agents are considered

For mild steroid-induced hyperglycemia, metformin or gliclazide have been used; DPP-4 inhibitor or GLP-1 receptor agonist therapy may be considered second line when pancreatitis and elevated lipase are absent. Moderate to severe hyperglycemia requires insulin therapy matched to steroid dose and pharmacodynamic profile. [1]
- Do not allow consideration of oral or incretin-based therapy to delay insulin when hyperglycemia is moderate to severe, persistent, or accompanied by acute illness. [1][11]

*Insulin strategy selection by observed steroid-associated glucose pattern. [1][8][11][13][22]*

| Pattern | Insulin approach | Key tradeoff or reassessment point |
| --- | --- | --- |
| Persistent hyperglycemia during any glucocorticoid regimen | Start scheduled insulin therapy. [11] | Review point-of-care glucose trends and glucocorticoid changes frequently. [1][12] |
| Morning steroid regimen with delayed daytime hyperglycemia | Use morning intermediate-acting isophane/NPH insulin or morning mixed insulin matched to the steroid profile. [1] | Fasting glucose can be misleadingly normal; use postprandial readings to titrate. [18][22] |
| Hospitalized type 2 diabetes receiving medium- or high-dose intermediate-acting corticosteroids | NPH or glargine may be used as basal insulin within basal-bolus treatment. [8] | The randomized trial found equal efficacy; choose according to regimen fit and monitoring capability. [8] |
| Longer-duration hyperglycemic effect across the day | Assess a basal-bolus strategy against serial daytime glucose values. [13][22] | Do not base adequacy solely on fasting glucose. [22] |

## Down-titrate insulin when steroid exposure falls

The highest preventable risk after achieving control is hypoglycemia during steroid tapering or cessation.

Whenever glucocorticoids are substantially reduced, reassess the diabetes regimen at the same time. Steroids are the principal driver of the added insulin requirement, and failure to lower glucose-lowering therapy as steroid exposure decreases is a frequent cause of hypoglycemia. [1]

At discharge or during outpatient steroid adjustment, give the patient a glucose-monitoring plan, hypoglycemia education if insulin or another hypoglycemia-producing therapy is used, and explicit instructions to contact the treating team when steroid dosing changes. Education should include symptoms of severe hyperglycemia and thresholds for hospital presentation. [1]

Patients with preexisting diabetes require particular attention because glucocorticoids can worsen existing hyperglycemia, while patients without known diabetes may have unmasked diabetes or transient steroid-related dysglycemia. Continued follow-up should therefore be guided by glucose trajectory after steroid withdrawal and baseline HbA1c when available. [18][1]
- Link every steroid prescription renewal, taper instruction, or discontinuation order to a review of insulin and other glucose-lowering medications. [1]
- Teach patients using insulin how to recognize and manage hypoglycemia before outpatient dose adjustments are made. [1]
- Escalate urgently rather than attempting routine outpatient titration when glucose and ketone thresholds indicate ketoacidosis or hyperosmolar risk. [1]

*Transition rules for insulin-treated steroid-induced hyperglycemia. [1][18]*

| Transition event | Required action | Safety rationale |
| --- | --- | --- |
| Substantial steroid dose reduction | Review and down-titrate glucose-lowering therapy. [1] | Insulin requirement can fall rapidly enough to cause hypoglycemia if doses are unchanged. [1] |
| Steroid discontinuation | Continue glucose surveillance and reassess whether ongoing diabetes treatment is needed. [1][18] | Hyperglycemia may resolve, persist as unmasked diabetes, or reflect preexisting diabetes. [18] |
| Outpatient insulin initiation or adjustment | Provide glucose-monitoring, severe-hyperglycemia, and hypoglycemia education. [1] | Both hyperglycemic crisis and treatment-related hypoglycemia require patient recognition and prompt action. [1] |

## References
1. Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations | Journal for ImmunoTherapy of Cancer — jitc.bmj.com — https://jitc.bmj.com/content/13/6/e011271
2. Management of diabetes and hyperglycaemia in the hospital — www.thelancet.com — https://www.thelancet.com/pdfs/journals/landia/PIIS2213-8587(20)30381-8.pdf
3. Fresh insights into glucocorticoid-induced diabetes mellitus and new ... — www.nature.com — https://www.nature.com/articles/s41574-022-00683-6
4. COVID-19 and diabetes mellitus: from pathophysiology to clinical management | Nature Reviews Endocrinology — www.nature.com — https://www.nature.com/articles/s41574-020-00435-4
5. Management of Glucocorticoid‐Induced Diabetes and/or Hyperglycemia - Endocrine and Metabolic Medical Emergencies - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/9781119374800.ch38
6. Glucocorticoid-Induced Hyperglycemia in Oncologic Outpatients: A Narrative Review Using the Quadruple Aim Framework - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1499267122000235
7. Glucocorticoid-Induced Hyperglycemia in Patients With Cancer: Mechanisms, Clinical Implications, and Management Strategies - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1530891X26000418
8. Randomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and respiratory disease - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0168822715003952#!
9. Steroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? A narrative review - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0168822717319368
10. Glucocorticoid-induced hyperglycemia in... : The Egyptian Journal of Haematology — journals.lww.com — https://journals.lww.com/egjh/fulltext/2020/45030/glucocorticoid_induced_hyperglycemia_in.2.aspx
11. An Endocrine Society Clinical Practice Guideline - Oxford Academic — academic.oup.com — https://academic.oup.com/jcem/article/97/1/16/2833111
12. Management of Hyperglycemia in Hospitalized Patients in Non ... — academic.oup.com — https://academic.oup.com/jcem/article-pdf/97/1/16/20288218/jcem0016.pdf
13. The Impact of Insulin Degludec on... : Journal of Diabetology — journals.lww.com — https://journals.lww.com/jodb/fulltext/2024/15020/the_impact_of_insulin_degludec_on.6.aspx
14. Glucocorticoid-induced hyperglycemia - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pubmed/23531958
15. 1104-P: Management of Corticosteroid-Related Hospital ... — diabetesjournals.org — https://diabetesjournals.org/diabetes/article/68/Supplement_1/1104-P/58584/1104-P-Management-of-Corticosteroid-Related
16. A Novel Algorithm for the Management of Inpatient COVID-19 ... — diabetesjournals.org — https://diabetesjournals.org/clinical/article/41/3/378/148554/A-Novel-Algorithm-for-the-Management-of-Inpatient
17. Metformin for Glucocorticoid-Induced Toxicity: Why Not? — diabetesjournals.org — https://diabetesjournals.org/care/article/48/5/688/158152/Metformin-for-Glucocorticoid-Induced-Toxicity-Why
18. Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem - PMC — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pmc/articles/5503862
19. Use of NPH versus Basal Bolus Insulin for Steroid Induced ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/21/NCT03511521/Prot_SAP_000.pdf
20. Pathways to Quality Inpatient Management of Hyperglycemia and Diabetes: A Call to Action | Diabetes Care | American Diabetes Association — diabetesjournals.org — https://diabetesjournals.org/care/article/36/7/1807/33203/Pathways-to-Quality-Inpatient-Management-of
21. What is the optimal time for measuring glucose concentration to detect steroid-induced hyperglycemia in patients with rheumatic diseases? - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0009912019301195
22. Insulin Dosing and Glycemic Outcomes Among Steroid-treated Hospitalized Patients — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1530891X22005006
23. Glucocorticoid-Induced Hyperglycemia - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1530891X20411711
24. [PDF] Steroid-induced hyperglycemia - ScienceDirect.com — www.sciencedirect.com — https://www.sciencedirect.com/science/article/am/pii/S0168822717319368

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.